Achieve Life Sciences

Management pre‑emptively raised substantial capital ahead of an expected CRL, pivoted drug‑product manufacturing to Adare’s U.S. facility, and is building an experienced launch team. The trade‑off is dilution and approval‑contingent warrants that may expand the share count upon success.

Debt terms are reasonable, and the company avoided costly bridge financings at a later, riskier moment. Overall, thoughtful but dilutive allocation in a pre‑revenue context.